- Home
- OLP vs AUTL Comparison
OLP vs AUTL Comparison
Compare OLP & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OLP
- AUTL
- Stock Information
- Founded
- OLP 1982
- AUTL 2014
- Country
- OLP United States
- AUTL United Kingdom
- Employees
- OLP N/A
- AUTL N/A
- Industry
- OLP Real Estate Investment Trusts
- AUTL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- OLP Real Estate
- AUTL Health Care
- Exchange
- OLP Nasdaq
- AUTL Nasdaq
- Market Cap
- OLP 569.9M
- AUTL 625.4M
- IPO Year
- OLP N/A
- AUTL 2018
- Fundamental
- Price
- OLP $24.06
- AUTL $2.44
- Analyst Decision
- OLP Strong Buy
- AUTL Strong Buy
- Analyst Count
- OLP 1
- AUTL 5
- Target Price
- OLP $28.00
- AUTL $9.32
- AVG Volume (30 Days)
- OLP 75.2K
- AUTL 1.9M
- Earning Date
- OLP 08-05-2025
- AUTL 08-07-2025
- Dividend Yield
- OLP 7.48%
- AUTL N/A
- EPS Growth
- OLP N/A
- AUTL N/A
- EPS
- OLP 1.35
- AUTL N/A
- Revenue
- OLP $92,152,000.00
- AUTL $9,011,000.00
- Revenue This Year
- OLP $11.87
- AUTL $461.76
- Revenue Next Year
- OLP $4.72
- AUTL $112.66
- P/E Ratio
- OLP $17.85
- AUTL N/A
- Revenue Growth
- OLP 3.31
- AUTL N/A
- 52 Week Low
- OLP $22.32
- AUTL $1.11
- 52 Week High
- OLP $30.45
- AUTL $5.00
- Technical
- Relative Strength Index (RSI)
- OLP 44.72
- AUTL 69.05
- Support Level
- OLP $23.91
- AUTL $2.24
- Resistance Level
- OLP $24.53
- AUTL $2.44
- Average True Range (ATR)
- OLP 0.52
- AUTL 0.12
- MACD
- OLP -0.07
- AUTL -0.01
- Stochastic Oscillator
- OLP 26.66
- AUTL 95.96
About OLP One Liberty Properties Inc.
One Liberty Properties Inc is a self-administered and self-managed real estate investment trust. It acquires, owns, and manages a geographically diversified portfolio consisting mainly of industrial and, to a lesser extent, retail properties, many of which are subject to long-term net leases. The trust has approximately one hundred two properties located across several states in the United States of America. A majority of its revenue is generated in the form of rental income.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.